BriaCell Therapeutics (TSE:BCT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BriaCell Therapeutics has dosed its first patient in a Phase 1/2 trial to test its innovative Bria-OTS™ immunotherapy for metastatic breast cancer, both as a standalone treatment and in combination with another cancer drug. This milestone highlights BriaCell’s commitment to advancing cancer treatments and improving patient outcomes through personalized and off-the-shelf therapies.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.